Premium
Promoter Hypermethylation as an Epigenetic Component in Type I and Type II Endometrial Cancers
Author(s) -
RISINGER JOHN I.,
MAXWELL G. LARRY,
BERCHUCK ANDREW,
BARRETT J. CARL
Publication year - 2003
Publication title -
annals of the new york academy of sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.712
H-Index - 248
eISSN - 1749-6632
pISSN - 0077-8923
DOI - 10.1111/j.1749-6632.2003.tb05975.x
Subject(s) - epigenetics , dna methylation , endometrial cancer , biology , gene silencing , gene , cancer research , genetics , methylation , promoter , cancer , gene expression
A bstract : Epigenetic mechanisms that result in aberrant gene expression are a prominent feature of many cancer types. One main epigenetic mechanism for gene silencing involves promoter hypermethylation. Type I and type II endometrial cancers exhibit differing clinical, histologic, and molecular genetic characteristics. We hypothesize that these differences also extend to epigenetic phenomena. Promoter methylation analysis of 11 genes in a panel of endometrial cancers supports this hypothesis. These initial data indicate that promoter hypermethylation events occur frequently in type 1 cancer and were not detected in type II cancers using this panel of loci. These data tend to support the hypothesis that type I and type II endometrial cancers will exhibit distinct patterns of gene silencing based on promoter hypermethylation events.